Powerful New Strategies for Drug Discovery
Analysis of Phase II drug failures (Arrowsmith 2011, Arrowsmith and Miller 2013) identifies lack of efficacy as the most frequent cause of attrition, suggesting that existing in vitro and in vivo disease models are not well-translated to human disease. Efficacy obstacles are especially problematic for clinical targets, such as the central nervous system (CNS), with notoriously unpredictive animal models. Together, CDI’s iCell® and MyCell® Products enable powerful new strategies for overcoming these hurdles:
- iCell Products: Differentiated human iPS cells drive disease modeling and drug screening initiatives in a variety of clinical areas including cardiac hypertrophy, Alzheimer’s disease, and diabetes
- MyCell Products and MyCell Disease & Diversity Products: Biologically relevant human cells from cohorts of donors with specific disease-associated genotypes and phenotypes fuel early-stage drug discovery efforts
Contact us to learn how CDI’s iPS cell platform gives scientists a more in-depth biological understanding of drug targets and improved target validation approaches.